his dataset supports a real-world pharmacovigilance study that evaluates and compares adverse events (AEs) associated with five biologics—efgartigimod, rozanolixizumab, eculizumab, ravulizumab, and zi
Background With an increasingly strained health system budgets, healthcare services need to continually demonstrate evidence of economic benefits. This study sought to evaluate the economic impact of
Introduction: Antibody–drug conjugates (ADCs) produce unparalleled efficacy in refractory neoplasms but can also lead to serious toxicities. Although ADC-related sepsis has been reported, the clinical
